|
Volumn 15, Issue 2, 2001, Pages 215-222
|
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected zambian adults
a a a a a a a |
Author keywords
Africa; Durability; HIV; Preventive therapy; Progression; Survival; Tuberculosis
|
Indexed keywords
CD4 ANTIGEN;
HEMOGLOBIN;
ISONIAZID;
NEOPTERIN;
PLACEBO;
PYRAZINAMIDE;
RIFAMPICIN;
ADULT;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DISEASE COURSE;
FEMALE;
FOLLOW UP;
HUMAN;
HUMAN CELL;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HUMAN TISSUE;
INFECTION RATE;
LONG TERM CARE;
MAJOR CLINICAL STUDY;
MALE;
MORTALITY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
TUBERCULOSIS;
ZAMBIA;
ADULT;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
ANTITUBERCULAR AGENTS;
CD4 LYMPHOCYTE COUNT;
COHORT STUDIES;
DISEASE PROGRESSION;
FEMALE;
FOLLOW-UP STUDIES;
HIV INFECTIONS;
HUMANS;
ISONIAZID;
MALE;
PYRAZINAMIDE;
RIFAMPIN;
TIME FACTORS;
TREATMENT OUTCOME;
TUBERCULOSIS;
ZAMBIA;
|
EID: 0035951509
PISSN: 02699370
EISSN: None
Source Type: Journal
DOI: 10.1097/00002030-200101260-00011 Document Type: Article |
Times cited : (131)
|
References (20)
|